Gain-of-function research

DC ElementWertSprache
dc.contributor.authorSaalbach, K.P.
dc.contributor.editorGadd, G.M.
dc.contributor.editorSariaslani, S.
dc.date.accessioned2023-02-17T12:15:22Z-
dc.date.available2023-02-17T12:15:22Z-
dc.date.issued2022
dc.identifier.isbn9780323989695
dc.identifier.issn0065-2164
dc.identifier.urihttp://osnascholar.ub.uni-osnabrueck.de/handle/unios/65934-
dc.description.abstractThe term Gain-of-Function (GoF) describes the gain of new functions by organisms through genetic changes, which can naturally occur or by experimental genetic modifications. Gain-of-Function research on viruses is enhancing transmissibility, virus replication, virulence, host range, immune evasion or drug and vaccine resistance to get insights into the viral mechanisms, to create and analyze animal models, to accelerate drug and vaccine development and to improve pandemic preparedness. A subset is the GoF research of concern (GOFROC) on enhanced potentially pandemic pathogens (ePPPs) that could be harmful for humans. A related issue is the military use of research as dual-use research of concern (DURC). Influenza and coronaviruses are main research targets, because they cause pandemics by airborne infections. Two studies on avian influenza viruses initiated a global debate and a temporary GoF pause in the United States which ended with a new regulatory framework in 2017. In the European Union and China, GoF and DURC are mainly covered by the legislation for laboratory safety and genetically modified organisms. After the coronavirus outbreaks, the GoF research made significant advances, including analyses of modified MERS-like and SARS-like viruses and the creation of synthetic SARS-CoV-2 viruses as a platform to generate mutations. The GoF research on viruses will still play an important role in future, but the need to clarify the differences and overlaps between GoF research, GOFROC and DURC and the need for specialized oversight authorities are still debated. © 2022 Elsevier Inc.
dc.description.sponsorshipNational Institutes of HealthNational Institutes of Health,NIH; Another research team achieved the modification of mouse-DPP 4 receptors to the human version by a plasmid-mediated gene targeting method. After inoculating hDPP4 knockin mice with MERS-CoV, there was virus replication without disease. After 30 in vivo serial passages, a mouse-adapted (MA) MERS-CoV MERS MA was created that caused fatal lung disease with diffuse alveolar damage and immune dysregulation; the study was supported by a NIH grant ( Li et al., 2017 ).
dc.language.isoen
dc.publisherAcademic Press Inc.
dc.relation.ispartofAdvances in Applied Microbiology
dc.subjectanimal
dc.subjectAvian influenza
dc.subjectBiosafety
dc.subjectBiosecurity
dc.subjectCOVID-19
dc.subjectDual-use research of concern DURC
dc.subjectEnhanced potential pandemic pathogen ePPP
dc.subjectGain of Function Mutation
dc.subjectGain-of-Function GoF
dc.subjectGain-of-Function research of concern GOFROC
dc.subjectgenetics
dc.subjecthuman
dc.subjectHumans
dc.subjectinfluenza
dc.subjectInfluenza, Human
dc.subjectMERS virus
dc.subjectpandemic
dc.subjectPandemics
dc.subjectSARS virus
dc.subjectSARS-CoV-2
dc.subjectSARS-CoV-2 (Covid-19)
dc.subjectUnited States
dc.subjectUnited States, Animals
dc.titleGain-of-function research
dc.typebook part
dc.identifier.doi10.1016/bs.aambs.2022.06.002
dc.identifier.pmid36243453
dc.identifier.scopus2-s2.0-85134159984
dc.identifier.urlhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85134159984&doi=10.1016%2fbs.aambs.2022.06.002&partnerID=40&md5=81d1cf88ac757292bab214ee3dd74107
dc.description.volume120
dc.description.startpage79
dc.description.endpage111
dcterms.isPartOf.abbreviationAdv. Appl. Microbiol.
Zur Kurzanzeige

Seitenaufrufe

22
Letzte Woche
0
Letzter Monat
0
geprüft am 19.05.2024

Google ScholarTM

Prüfen

Altmetric